- Home
- BCLI vs ADIL Comparison
BCLI vs ADIL Comparison
Compare BCLI & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- ADIL
- Stock Information
- Founded
- BCLI 2000
- ADIL 2010
- Country
- BCLI United States
- ADIL United States
- Employees
- BCLI N/A
- ADIL N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- ADIL Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- ADIL Health Care
- Exchange
- BCLI Nasdaq
- ADIL Nasdaq
- Market Cap
- BCLI 6.4M
- ADIL 6.5M
- IPO Year
- BCLI N/A
- ADIL 2018
- Fundamental
- Price
- BCLI $1.21
- ADIL $1.06
- Analyst Decision
- BCLI Strong Buy
- ADIL Strong Buy
- Analyst Count
- BCLI 1
- ADIL 1
- Target Price
- BCLI $30.00
- ADIL $8.00
- AVG Volume (30 Days)
- BCLI 118.2K
- ADIL 222.2K
- Earning Date
- BCLI 11-14-2024
- ADIL 11-13-2024
- Dividend Yield
- BCLI N/A
- ADIL N/A
- EPS Growth
- BCLI N/A
- ADIL N/A
- EPS
- BCLI N/A
- ADIL N/A
- Revenue
- BCLI N/A
- ADIL N/A
- Revenue This Year
- BCLI N/A
- ADIL N/A
- Revenue Next Year
- BCLI N/A
- ADIL N/A
- P/E Ratio
- BCLI N/A
- ADIL N/A
- Revenue Growth
- BCLI N/A
- ADIL N/A
- 52 Week Low
- BCLI $1.05
- ADIL $0.77
- 52 Week High
- BCLI $11.85
- ADIL $4.17
- Technical
- Relative Strength Index (RSI)
- BCLI 23.69
- ADIL 52.82
- Support Level
- BCLI $1.05
- ADIL $0.98
- Resistance Level
- BCLI $1.95
- ADIL $1.28
- Average True Range (ATR)
- BCLI 0.20
- ADIL 0.07
- MACD
- BCLI -0.00
- ADIL 0.00
- Stochastic Oscillator
- BCLI 15.84
- ADIL 29.03
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.